UBUlrich Buell

Ulrich Buell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ulrich Buell has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study

    by Bernd Gagel, Patrick Reinartz, Cengiz Demirel, Hans J Kaiser, Michael Zimny, Marc Piroth, Michael Pinkawa, Sven Stanzel, Branka Asadpour, Kurt Hamacher, et al.

    Background: Experimental and clinical evidence suggest that hypoxia in solid tumours reduces their sensitivity to conventional treatment modalities modulating response to ionizing radiation or chemotherapeutic agents. The aim of the present study was to show the feasibility of determining radiotherapeutically relevant hypoxia and early tumour response by ([18F] Fluoromisonidazole (FMISO) and [18F]-2-fluoro-2'-deoxyglucose (FDG) PET. Methods: Eight patients with non-small-cell lung cancer underwent PET scans. Tumour tissue oxygenation was measured with FMISO PET, whereas tumour glucose metabolism was measured with FDG PET. All PET studies were carried out with an ECAT EXACT 922/47® scanner with an axial field of view of 16.2 cm. FMISO PET consisted of one static scan of the relevant region, performed 180 min after intravenous administration of the tracer. The acquisition and reconstruction parameters were as follows: 30 min emission scanning and 4 min transmission scanning with 68-Ge/68-Ga rod sources. The patients were treated with chemotherapy, consisting of 2 cycles of gemcitabine (1200 mg/m2) and vinorelbine (30 mg/m2) followed by concurrent radio- (2.0 Gy/d; total dose 66.0 Gy) and chemotherapy with gemcitabine (300–500 mg/m2) every two weeks. FMISO PET and FDG PET were performed in all patients 3 days before and 14 days after finishing chemotherapy. Results: FMISO PET allowed for the qualitative and quantitative definition of hypoxic sub-areas which may correspond to a localization of local recurrences. In addition, changes in FMISO and FDG PET measure the early response to therapy, and in this way, may predict freedom from disease, as well as overall survival. Conclusion: These preliminary results warrant validation in larger trials. If confirmed, several novel treatment strategies may be considered, including the early use of PET to evaluate the effectiveness of the selected therapy.


  • 18FDG-PET in 733 consecutive patients with or without side-by-side CT evaluation: analysis of 921 lesions.

    by U Buell, F J Wieres, W Schneider, P Reinartz

    Side-by-side analysis of CT and conventional (18)FDG-PET in oncological imaging is well established. AIM of this study was to find out which patients or diagnostic groups may benefit the most from the newly introduced integrated PET/CT scanners. 407 consecutively admitted oncological patients with accompanying CT (groups A-D) and 326 patients without CT (groups E-G) were examined by conventional ring PET. Two nuclear medicine physicians and two radiologists assessed each patient's PET and CT scans for pathological lesions with regard to localisation and infiltration of adjacent anatomical structures. Patients without pathological PET findings were assigned to groups A (with CT) or E (without CT). If the localisation and/or extent of a pathological PET focus could only be assessed by taking into account the CT scan, the patient was assigned to group C (with CT) or G (without CT). If PET alone was sufficient for both questions the patient was assigned to groups B (with CT) or F (without CT). If neither method allowed for a precise lesion characterisation, the patient was assigned to group D. 38.6% (A, E) of all patients were PET-negative. PET alone sufficed in 20.6% (B, F). Side-by-side reading of PET and CT was needed for 43.5% (C) of patients referred to PET with a current CT. Side-by-side reading of CT and PET did not suffice for 7.3% (D) of patients in that cohort. A total of 28.2% (G) of the cases without CT would have profited from it. The most frequent oncological diagnoses in group D (PET and conventional CT not sufficient) were bronchial carcinoma with abdominal lesions, while in group G (without CT but CT required) head/neck cancer with thoracic lesions was predominant. Side-by-side reading of PET and already existing conventional CT failed to yield conclusive data with regard to lesion characterisation in only 7.4% of patients so that PET/CT might have been helpful in these cases. 28.2% of the patients without current CT would have profited from an initial PET/CT examination. On the other hand, 59.2% of all patients (negative PET or PET alone sufficing) did not require a CT for lesion characterisation.


  • 18FDG-PET in 733 consecutive patients with or without side-by-side CT evaluation

    by F. J. Wieres, W. Schneider, P. Reinartz, U. Buell

    Side-by-side analysis of CT and conventional 18FDG-PET in oncological imaging is well established. Aim of this study was to find out which patients or diagnostic groups may benefit the most from the newly introduced integrated PET/CT scanners. Patients, methods: 407 consecutively admitted oncological patients with accompanying CT (groups A-D) and 326 patients without CT (groups E-G) were examined by conventional ring PET. Two nuclear medicine physicians and two radiologists assessed each patient’s PET and CT scans for pathological lesions with regard to localisation and infiltration of adjacent anatomical structures. Patients without pathological PET findings were assigned to groups A (with CT) or E (without CT). If the localisation and/or extent of a pathological PET focus could only be assessed by taking into account the CT scan, the patient was assigned to group C (with CT) or G (without CT). If PET alone was sufficient for both questions the patient was assigned to groups B (with CT) or F (without CT). If neither method allowed for a precise lesion characterisation, the patient was assigned to group D. Results: 38.6% (A, E) of all patients were PET-negative. PET alone sufficed in 20.6% (B, F). Side-by-side reading of PET and CT was needed for 43.5% (C) of patients referred to PET with a current CT. Side-by-side reading of CT and PET did not suffice for 7.3% (D) of patients in that cohort. A total of 28.2% (G) of the cases without CT would have profited from it. The most frequent oncological diagnoses in group D (PET and conventional CT not sufficient) were bronchial carcinoma with abdominal lesions, while in group G (without CT but CT required) head/neck cancer with thoracic lesions was predominant. Conclusions: Side-by-side reading of PET and already existing conventional CT failed to yield conclusive data with regard to lesion characterisation in only 7.4% of patients so that PET/CT might have been helpful in these cases. 28.2% of the patients without current CT would have profited from an initial PET/CT examination. On the other hand, 59.2% of all patients (negative PET or PET alone sufficing) did not require a CT for lesion characterisation. Die vergleichende Befundung von CT und konventionellem 18FDG-PET ist seit vielen Jahren etabliert. Ziel der Studie war die Beantwortung der Frage, welche Patienten bzw. Diagnosegruppen von integrierten PET/CTScannern profitieren. Patienten, Methoden: Mit einem konventionellem Ring-PET wurden 407 konsekutive Tumorpatienten mit (Gruppen A-D) und 326 Patienten ohne begleitendes CT (Gruppen E-G) erfasst. Je zwei Nuklearmediziner und Radiologen bewerteten die PETund CT-Aufnahmen hinsichtlich der Lokalisation von Herdbefunden sowie einer möglichen Infiltration benach-barter Strukturen. Patienten ohne pathologische PETBefunde wurden den Gruppen A (mit CT) bzw. E (ohne CT) zugeteilt. Wenn zur Beurteilung einer PET-Läsion das Begleit-CT hinzugezogen werden musste, gelangte der Patient in die Gruppe C; wenn hingegen das PET hierfür alleine genügte, in Gruppe B (mit CT) oder F (ohne CT). Waren beide Verfahren unzureichend, wurde der Patient der Gruppe D zugeteilt. Fälle der Gruppe G hätten ein CT erfordert, waren jedoch ohne CT zum PET überwiesen worden. Ergebnisse: 38,6% (A, E) aller Patienten zeigten keinen pathologischen PET-Befund. 20,6% (B, F) der Patienten konnten mit dem PET allein beurteilt werden. Die CT war notwendig bei 43,5% (C) der Patienten, die mit einem CT zum PET überwiesen worden waren. Nicht ausreichend war die kombinierte Auswertung von PET und CT bei 7,3% (D) der Patienten. Fälle ohne Begleit-CT hätten zu 28,2% (G) von einem CT profitiert. Häufigste Tumordiagnose in Gruppe D war das Bronchial-karzinom mit abdominellen Läsionen, für die Gruppe G dagegen Hals-Kopf-Tumore mit thorakaler Beteiligung. Schlussfolgerungen: Die gemeinsame Befundung von PET- und CT-Aufnahmen aus nicht integrierten Geräten erlaubte bei nur 7,4% der Patienten keine eindeutige Charakterisierung der Läsionen. Auch 28,2% der Patienten ohne Begleit-CT hätten von einem primären PET/CT profitiert. Andererseits war bei 59,2% aller Patienten (PET negativ oder ausreichend) kein CT zur Charakterisierung der Läsionen erforderlich.